Greenwich LifeSciencesGLSI -6.78%33 Current Ratio is 2.01 as of Mar. 2026, which is 89% below its 10-year median of 18.95. GuruFocus rates GLSI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Greenwich LifeSciences ranks worse than 68.38% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Greenwich LifeSciences's current ratio for the quarter that ended in Mar. 2026 was 2.01.
Greenwich LifeSciences has a current ratio of 2.01. It generally indicates good short-term financial strength.
The historical rank and industry rank for Greenwich LifeSciences's Current Ratio or its related term are showing as below:
GLSI'
s Current Ratio Range Over the Past 10 Years
Min: 0.01 Med: 18.95 Max: 81.92
Current: 2.01
During the past 8 years, Greenwich LifeSciences's highest Current Ratio was 81.92. The lowest was 0.01. And the median was 18.95.
GLSI's Current Ratio is ranked worse than 68.38% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs GLSI: 2.01
Greenwich LifeSciences (NAS:GLSI) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Greenwich LifeSciences Current Ratio Related Terms
Greenwich LifeSciences Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GLSI vs LRMR, RGNX, PBYI: Current Ratio Comparison
For the Biotechnology subindustry, Greenwich LifeSciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greenwich LifeSciences Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Greenwich LifeSciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Greenwich LifeSciences (GLSI) has a Current Ratio of 2.01 as of Mar. 2026. This is 89% below median its historical median of 18.95. Over the past decade, Greenwich LifeSciences' Current Ratio has ranged from 0.01 to 81.92. According to the industry distribution chart, Greenwich LifeSciences ranks #969 out of 1417 companies in the Biotechnology industry, placing it in the top 68.4%.
Is Greenwich LifeSciences' Current Ratio too high?
Greenwich LifeSciences' current Current Ratio of 2.01 is 89% below median its 10-year median of 18.95. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 81.92. The Biotechnology industry median Current Ratio is 3.89. Greenwich LifeSciences' value of 2.01 is 48.3% below this industry median. Based on the distribution chart, Greenwich LifeSciences ranks #969 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Greenwich LifeSciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Greenwich LifeSciences' Current Ratio compare to LRMR and RGNX?
According to the Biotechnology industry distribution chart, Greenwich LifeSciences ranks #969 out of 1417 companies for Current Ratio. This places Greenwich LifeSciences in the lower half of its industry. The industry median Current Ratio is 3.89. Greenwich LifeSciences' value of 2.01 is 48.3% below this benchmark. Historically, Greenwich LifeSciences' own Current Ratio has ranged from 0.01 to 81.92 over the past decade. While the company's 10-year median is 18.95 vs. the industry median of 3.89, Greenwich LifeSciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Greenwich LifeSciences's current Current Ratio of 2.01 is 48.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Greenwich LifeSciences's current Current Ratio is 2.01, which is 89% below median its own 10-year median of 18.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenwich LifeSciences stock overvalued right now?
Greenwich LifeSciences (GLSI) has a current Current Ratio of 2.01. The current Current Ratio is 2.01, which is 89% below median its 10-year median of 18.95 and 48.3% below the Biotechnology industry median of 3.89. Greenwich LifeSciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Greenwich LifeSciences (GLSI), the current Current Ratio is 2.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
33GF Score
Get the complete analysis for GLSI
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLSI has been successfully added to your 
